1 Glorious Growth Stock Down 78% to Buy on the Dip in September

Docusign generated fiscal Q2 2027 revenue of $875.7 million, above its $865 million-$869 million forecast, up 9% year over year; GAAP net income rose 23% to $77.7 million as operating expenses increased only 2%. Its AI-powered Intelligent Agreement Management platform has reached roughly 40,000 of 1.9 million paying customers, and management expects IAM to contribute about 18.5% of $3.55 billion in fiscal 2027 ARR, versus 2.3% at the end of fiscal 2025. Shares remain down 78% from their 2021 peak but trade at 4.1x sales, below the company's 11.8x post-IPO average, supporting the article's constructive long-term view.

Analysis

The investable question is whether IAM creates net-new contract-lifecycle spend or merely repackages Docusign’s installed e-signature base. The ARR mix target implies a roughly $650M product category, but the market will require evidence that this is incremental: rising net revenue retention, larger enterprise ACVs, and reduced churn rather than seat migration into bundled plans. If validated over the next 1-3 quarters, DOCU can rerate from a mature workflow SaaS multiple toward the higher end of the contract-management peer set; if not, the current growth/profit tradeoff leaves limited multiple support.

The key competitive risk is distribution, not model quality. Adobe (ADBE), Salesforce (CRM), and ServiceNow (NOW) already control adjacent document, customer, and workflow systems and can use bundled AI features to cap DOCU’s pricing power; private CLM vendors such as Icertis, Ironclad, and Conga remain more direct enterprise substitutes. Conversely, DOCU’s agreement data layer can become defensible if it drives renewals, compliance workflows, and revenue-leakage recovery that customers cannot replicate through generic copilots.

Near-term upside is likely catalyst-dependent rather than sentiment-driven: the next two earnings reports need to show IAM adoption translating into billings/remaining performance obligations acceleration and durable operating leverage after stock-based compensation. The contrarian view is that consensus may be underwriting too much AI optionality before monetization is proven; a weak enterprise expansion signal would expose DOCU as a low-single-digit-growth SaaS asset despite headline AI adoption. Falsify a constructive thesis if revenue growth remains below 10% while IAM mix rises, which would indicate cannibalization, or if GAAP margin improvement reverses as sales investment resumes.

Key Decisions for Investors

• Maintain DOCU on a 1-3 month earnings watch rather than establish a full long immediately. Upgrade to a long only if billings or RPO growth accelerates by at least 3 percentage points and management raises full-year ARR guidance; target a 15-25% rerating versus approximately 10-15% downside if growth remains stagnant.
• For a defined-risk event position, consider a small DOCU call spread dated 1-2 months beyond the next earnings release, funded only where implied volatility is below the stock’s prior post-earnings realized move. The trade requires confirmation of option pricing and consensus estimates; do not initiate on the article alone.
• Use a relative-value framework: long DOCU / short ADBE only after IAM enterprise ACV and retention data improve, as DOCU has greater rerating torque while ADBE has broader AI monetization already embedded. Exit if DOCU’s growth premium fails to emerge within two reporting periods.
• Monitor ADBE, CRM, and NOW product releases and discounting in contract workflow. Material bundling or price concessions are a signal to avoid DOCU longs because the downside case is margin compression before IAM reaches sufficient scale.